Tensha Therapeutics, Inc.: Series A $15M

Posted in I - Series A, Q - 3Q11, R - NORTH EAST, X - Epigenetics, X - Oncology, XX - MA

Tensha Therapeutics (Cambridge, MA) a preclinical-stage pharmaceutical company focused on midline carcinoma, acute myeloid leukemias and multiple myeloma, closed a $15M Series A financing. Participants include HealthCare Ventures.

Aug

2011

Constellation Pharmaceuticals, Inc.: Series B $15M

Posted in I - Series B, Q - 2Q11, R - NORTH EAST, X - Epigenetics, X - Immunology, X - Inflammation, X - Oncology, XX - MA

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on small molecule therapeutics against chromatin-based targets to treat cancer and inflammatory disorders, closed a $15M Series B financing bringing the total round to $37M. Participants include S.R. One, Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.
The 2Q11 OnBioVC Trend Analysis will be [...]

Jun

2010

Constellation Pharmaceuticals, Inc.: Series B $4.8M

Posted in I - Series B, Q - 2Q10, R - NORTH EAST, X - Epigenetics, X - Oncology, XX - MA

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on epigenetic therapeutic development in the field of oncology, closed a $4.8M Series B financing bringing the total round to $22M. Participants include S.R. One, Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.

Feb

2010

Epizyme, Inc.: Series B $8M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Epigenetics, X - Oncology, X - Therapeutic Platform, XX - MA

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications, closed a $8M Series B financings, bringing the total round to $40M. Participants include New Enterprise Associates, Bay City Capital, Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers.
Note: 2009 Year-in-Review Trend Analysis Coming 15 [...]

Jan

2010

Epizyme, Inc.: Series B $32M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Epigenetics, X - Oncology, X - Therapeutic Platform, XX - MA

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications. Participants include Bay City Capital, Amgen Ventures, Astellas Venture Management, MPM Capital and Kleiner Perkins Caufield and Byers.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Oct

2009

Constellation Pharmaceuticals, Inc. Series B $17.2M

Posted in I - Series B, Q - 3Q09, R - NORTH EAST, X - Epigenetics, X - Oncology, XX - MA

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on epigenetic therapeutic development in the field of oncology, closed a $17.2M Series B financing. Participants include Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.

Nov

2008

Constellation Pharmaceuticals: Series A $32M

Posted in I - Series A, Q - 2Q08, R - NORTH EAST, X - Epigenetics

Constellation Pharmaceuticals (Cambridge, MA) development-stage biopharmaceutical company focused on discovering and developing novel drugs targeting selective regulators of epgenetic function, closed a $32M Series A financing. Participants include Third Rock Ventures, Column Group, and Venrock

to top of page...